Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.

Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H.

Clin Ophthalmol. 2013;7:515-20. doi: 10.2147/OPTH.S40147. Epub 2013 Mar 12.

2.

Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.

Kumagami T, Wakiyama H, Kusano M, Kajiyama A, Miura Y, Uematsu M, Yoneda A, Kurihara J, Suzuma K, Kitaoka T.

J Ocul Pharmacol Ther. 2014 May;30(4):340-5. doi: 10.1089/jop.2013.0132. Epub 2014 Feb 27.

PMID:
24576066
3.

Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.

Whitson JT, Petroll WM.

Adv Ther. 2012 Oct;29(10):874-88. doi: 10.1007/s12325-012-0057-1. Epub 2012 Oct 10.

PMID:
23065664
4.

Polyoxyethylene hydrogenated castor oil modulates benzalkonium chloride toxicity: comparison of acute corneal barrier dysfunction induced by travoprost Z and travoprost.

Uematsu M, Kumagami T, Shimoda K, Kusano M, Teshima M, To H, Kitahara T, Kitaoka T, Sasaki H.

J Ocul Pharmacol Ther. 2011 Oct;27(5):437-44. doi: 10.1089/jop.2010.0175. Epub 2011 Jun 29.

PMID:
21714635
5.

Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.

Brignole-Baudouin F, Riancho L, Liang H, Baudouin C.

Curr Eye Res. 2011 Nov;36(11):979-88. doi: 10.3109/02713683.2011.578781.

PMID:
21999224
6.

The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.

Pellinen P, Huhtala A, Tolonen A, Lokkila J, Mäenpää J, Uusitalo H.

Curr Eye Res. 2012 Feb;37(2):145-54. doi: 10.3109/02713683.2011.626909. Epub 2011 Nov 3.

PMID:
22049909
7.

In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.

Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F.

Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4594-9.

PMID:
16303954
8.

Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.

Liang H, Brignole-Baudouin F, Riancho L, Baudouin C.

Ophthalmic Res. 2012;48(2):89-101. doi: 10.1159/000335984.

PMID:
22473057
9.

Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.

Ammar DA, Noecker RJ, Kahook MY.

Adv Ther. 2010 Nov;27(11):837-45. doi: 10.1007/s12325-010-0070-1. Epub 2010 Oct 7.

PMID:
20931366
10.

In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.

Kahook MY, Ammar DA.

J Ocul Pharmacol Ther. 2010 Jun;26(3):259-63. doi: 10.1089/jop.2010.0003.

PMID:
20565312
11.

Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits.

Giannico AT, Lima L, Shaw GC, Russ HH, Froes TR, Montiani-Ferreira F.

Arq Bras Oftalmol. 2016 Feb;79(1):33-6. doi: 10.5935/0004-2749.20160010.

12.
13.
16.

In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.

Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C.

Curr Eye Res. 2008 Apr;33(4):303-12. doi: 10.1080/02713680801971857.

PMID:
18398704
17.

In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.

Baudouin C, Riancho L, Warnet JM, Brignole F.

Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4123-8.

PMID:
17724196
18.

Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit.

Chen W, Dong N, Huang C, Zhang Z, Hu J, Xie H, Pan J, Liu Z.

PLoS One. 2014 Mar 14;9(3):e89205. doi: 10.1371/journal.pone.0089205. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98378.

19.

Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.

Stewart WC, Stewart JA, Jenkins JN, Jackson AL.

J Glaucoma. 2003 Dec;12(6):475-9.

PMID:
14646682
20.

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.

Katz G, Springs CL, Craven ER, Montecchi-Palmer M.

Clin Ophthalmol. 2010 Nov 3;4:1253-61. doi: 10.2147/OPTH.S14113.

Supplemental Content

Support Center